Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 8:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Melanocytoma Clear all
Withdrawn Phase 1Phase 2 Interventional Accepts healthy volunteers

Evaluation of 20% Betulinic Acid Ointment for Treatment of Dysplastic Nevi (Moderate to Severe Dysplasia)

NCT00346502
View directory record Official record
Conditions
Dysplastic Nevus Syndrome
Interventions
20% betulinic acid ointment, BA
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 27, 2021 · Synced Jun 25, 2026, 8:14 AM EDT
Completed No phase listed Observational

National Registry for Ichthyosis and Related Disorders

NCT00074685
View directory record Official record
Conditions
Darier Disease, Hailey-Hailey Disease, Hyperkeratosis, Epidermolytic, Ichthyosis, Ichthyosis, Lamellar, Ichthyosis, X-Linked, Keratoderma
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2004
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Jun 25, 2026, 8:14 AM EDT
Suspended Phase 1Phase 2 Interventional

Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS)

NCT03208296
View directory record Official record
Conditions
Basal Cell Carcinoma in Basal Cell Nevus Syndrome
Interventions
ASN-002
Biological
Lead sponsor
Ascend Biopharmaceuticals Ltd
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 5, 2023 · Synced Jun 25, 2026, 8:14 AM EDT
Not listed Early Phase 1 Interventional

Burosumab for CSHS

NCT03993821
View directory record Official record
Conditions
Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS), Epidermal Nevus Syndrome
Interventions
Burosumab
Drug
Lead sponsor
Laura Tosi
Other
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 6, 2022 · Synced Jun 25, 2026, 8:14 AM EDT
Completed Phase 2 Interventional Results available

Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas

NCT02828111
View directory record Official record
Conditions
Basal Cell Carcinomas
Interventions
Patidegib, Vehicle gel
Drug
Lead sponsor
PellePharm, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Jun 25, 2026, 8:14 AM EDT
Completed No phase listed Observational

Risk Stratification Among Individuals Who Have Many Moles on Their Skin

NCT03080948
View directory record Official record
Conditions
High-Risk Nevus Phenotype
Interventions
survey, Saliva samples
Behavioral · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
4
States / cities
Basking Ridge, New Jersey • Harrison, New York • Hauppauge, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Jun 25, 2026, 8:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Training Primary Care Physicians to Perform Melanoma Opportunistic Surveillance

NCT02385253
View directory record Official record
Conditions
Melanoma, Nevi, Skin Moles
Interventions
Educational training program
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Jun 25, 2026, 8:14 AM EDT
Completed No phase listed Observational

Assessment of Digital Imaging as a Tool for Diagnosing Psoriasis, Hand Rashes and Unusual Moles

NCT00005781
View directory record Official record
Conditions
Dermatitis, Nevus, Psoriasis
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 25, 2026, 8:14 AM EDT
Completed Phase 1Phase 2 Interventional

Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)

NCT04364230
View directory record Official record
Conditions
Melanoma, Ocular Melanoma, Uveal Melanoma
Interventions
6MHP, NeoAg-mBRAF, PolyICLC, CDX-1140
Drug
Lead sponsor
Craig L Slingluff, Jr
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Cleveland, Ohio • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 15, 2024 · Synced Jun 25, 2026, 8:14 AM EDT
Terminated No phase listed Observational

In Vivo Confocal Microscopy Study of Pigmented Conjunctival Lesions

NCT01993654
View directory record Official record
Conditions
Nevus, Racial Melanosis, Primary Acquired Melanosis, Conjunctival Malignant Melanoma
Interventions
HRT III with Non-Contact Cornea Rostock Module
Procedure
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
3
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2016 · Synced Jun 25, 2026, 8:14 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of Light Dose in Subjects With PWB Treated With Hemoporfin PDT

NCT05171894
View directory record Official record
Conditions
Port-wine Birthmarks, Port-Wine Stain, Nevus Flammeus
Interventions
Hemopfin+Green Light, Vehicle+Green Light
Drug · Device
Lead sponsor
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Irvine, California • San Diego, California • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Jun 25, 2026, 8:14 AM EDT
Recruiting No phase listed Observational

Familial Investigations of Childhood Cancer Predisposition

NCT03050268
View directory record Official record
Conditions
Acute Leukemia, Adenomatous Polyposis, Adrenocortical Carcinoma, AML, BAP1 Tumor Predisposition Syndrome, Carney Complex, Choroid Plexus Carcinoma, Constitutional Mismatch Repair Deficiency Syndrome, Diamond-Blackfan Anemia, DICER1 Syndrome, Dyskeratosis Congenita, Emberger Syndrome, Familial Acute Myeloid Leukemia, Familial Adenomatous Polyposis, Fanconi Anemia, Familial Cancer, Familial Wilms Tumor, Familial Neuroblastoma, GIST, Hereditary Breast and Ovarian Cancer, Hereditary Paraganglioma-Pheochromocytoma Syndrome, Hodgkin Lymphoma, Juvenile Polyposis, Li-Fraumeni Syndrome, Lynch Syndrome, MDS, Melanoma Syndrome, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2, Neuroblastoma, Neurofibromatosis Type 1, Neurofibromatosis Type II, Nevoid Basal Cell Carcinoma Syndrome, Non Hodgkin Lymphoma, Noonan Syndrome and Other Rasopathy, Overgrowth Syndromes, Pancreatic Cancer, Peutz-Jeghers Syndrome, Pheochromocytoma/Paraganglioma, PTEN Hamartoma Tumor Syndrome, Retinoblastoma, Rhabdoid Tumor Predisposition Syndrome, Rhabdomyosarcoma, Rothmund-Thomson Syndrome, Tuberous Sclerosis, Von Hippel-Lindau Disease
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2037
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jun 25, 2026, 8:14 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Optical Biopsy of Human Skin in Conjunction With Laser Treatment

NCT00540566
View directory record Official record
Conditions
Malignant Melanoma, Merkel Cell Carcinoma, Basal Cell Carcinoma, Squamous Cell Carcinoma, Atypical Nevi, Congenital Nevi, Seborrheic Keratosis, Paget's Disease, Dermatofibroma, Kaposi's Sarcoma, Port Wine Stain, Hemangioma, Tattoos, Scleroderma, Burns
Interventions
Optical Biopsy imaging
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 75 Years
Enrollment
113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2008
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Jun 25, 2026, 8:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Internet-based Intervention for Skin Self-Examination in Participants With Increased Risk for Melanoma

NCT03725449
View directory record Official record
Conditions
Dysplastic Nevus, Health Status Unknown, Melanoma, No Evidence of Disease
Interventions
Best Practice, mySmartCheck, Survey Administration
Other · Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 89 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 13, 2022 · Synced Jun 25, 2026, 8:14 AM EDT
Completed No phase listed Observational

Skin Fluorescent Imaging (SFI) System in Patients With Nevi

NCT04368247
View directory record Official record
Conditions
Nevus, Dysplasia; Epithelial
Interventions
Skin Fluorescent Imaging
Diagnostic Test
Lead sponsor
Orlucent, Inc
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Timeline
2020 – 2023
U.S. locations
4
States / cities
Fremont, California • Northridge, California • Vallejo, California + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Jun 25, 2026, 8:14 AM EDT
Not listed No phase listed Observational

Pancreatic Cancer Early Detection Program

NCT02206360
View directory record Official record
Conditions
Pancreatic Cancer, Pancreas Cancer, Pancreatic Adenocarcinoma, Familial Pancreatic Cancer, BRCA 1/2, HNPCC, Lynch Syndrome, Hereditary Pancreatitis, FAMMM, Familial Atypical Multiple Mole Melanoma, Peutz Jeghers Syndrome
Interventions
Endoscopic Ultrasound, Magnetic Resonance Imaging (MRI)
Procedure
Lead sponsor
White Plains Hospital
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
White Plains, New York
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Jun 25, 2026, 8:14 AM EDT
Completed Phase 2 Interventional

Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors

NCT00521118
View directory record Official record
Conditions
Complete Hydatidiform Mole, Non-Metastatic Gestational Trophoblastic Tumor, Partial Hydatidiform Mole
Interventions
Laboratory Biomarker Analysis, Therapeutic Conventional Surgery
Other · Procedure
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
28
States / cities
Mountain View, California • Palo Alto, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2017 · Synced Jun 25, 2026, 8:14 AM EDT
Completed Early Phase 1 Interventional

Pilot Study Evaluating Sulforaphane in Atypical Nevi-Precursor Lesions

NCT01568996
View directory record Official record
Conditions
Atypical Nevi, Melanoma
Interventions
broccoli sprout extract - sulforaphane (BSE-SFN)
Drug
Lead sponsor
John Kirkwood
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 8, 2018 · Synced Jun 25, 2026, 8:14 AM EDT
Completed Phase 3 Interventional Results available

Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia

NCT01535053
View directory record Official record
Conditions
Choriocarcinoma, FIGO Stage I Gestational Trophoblastic Tumor, FIGO Stage II Gestational Trophoblastic Tumor, FIGO Stage III Gestational Trophoblastic Tumor, Hydatidiform Mole
Interventions
Dactinomycin, Leucovorin Calcium, Methotrexate, Quality-of-Life Assessment
Biological · Drug · Other
Lead sponsor
GOG Foundation
Network
Eligibility
18 Years and older · Female only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
267
States / cities
Anchorage, Alaska • Phoenix, Arizona • Burbank, California + 181 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2022 · Synced Jun 25, 2026, 8:14 AM EDT
Recruiting No phase listed Observational

Lymphatic Anomalies Registry for the Assessment of Outcome Data

NCT02399527
View directory record Official record
Conditions
Lymphatic Malformation, Generalized Lymphatic Anomaly (GLA), Central Conducting Lymphatic Anomaly, CLOVES Syndrome, Gorham-Stout Disease ("Disappearing Bone Disease"), Blue Rubber Bleb Nevus Syndrome, Kaposiform Lymphangiomatosis, Kaposiform Hemangioendothelioma/Tufted Angioma, Klippel-Trenaunay Syndrome, Lymphangiomatosis
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2035
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Jun 25, 2026, 8:14 AM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome

NCT06050122
View directory record Official record
Conditions
Gorlin Syndrome
Interventions
Patidegib Topical Gel, Patidegib Topical Gel with no active patidegib
Drug
Lead sponsor
Sol-Gel Technologies, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
24
States / cities
Rogers, Arkansas • Fremont, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Jun 25, 2026, 8:14 AM EDT
Recruiting Phase 1 Interventional

Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease

NCT03025256
View directory record Official record
Conditions
Acral Lentiginous Melanoma, Central Nervous System Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Leptomeningeal Neoplasm, Melanocytoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Melanoma, Metastatic Mucosal Melanoma, Metastatic Uveal Melanoma, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Lumbar Puncture, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography
Procedure · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jun 25, 2026, 8:14 AM EDT
Terminated No phase listed Observational

Detection of Choroidal Nevus Cells in Vitrectomy Fluid

NCT01324609
View directory record Official record
Conditions
Nevus
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Jun 25, 2026, 8:14 AM EDT
Completed Phase 4 Interventional Results available

A Trial to Assess the Safety and Efficacy of KRN23 in Epidermal Nevus Syndrome (ENS)

NCT04320316
View directory record Official record
Conditions
Epidermal Nevus Syndrome
Interventions
Crysvita (burosumab-twza) Treatment
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
6 Months and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Jun 25, 2026, 8:14 AM EDT